cannabis transdermal (AQS1304)
/ Aequus Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
December 25, 2024
Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities.
(PubMed, Med Cannabis Cannabinoids)
- "This novel transdermal medical cannabis formulation (THC:CBD:CBN) demonstrated significant therapeutic efficacy in ameliorating painful DPN symptoms while maintaining a favorable safety profile. These findings provide robust clinical evidence supporting its potential as an innovative therapeutic option for managing painful DPN."
Clinical • Journal • Dermatology • Diabetic Neuropathy • Neuralgia • Pain • Peripheral Neuropathic Pain
July 17, 2024
Efficacy and Safety of Cannabis Transdermal Patch for Alleviating Psoriasis Symptoms: Protocol for a Randomized Controlled Trial (CanPatch).
(PubMed, Med Cannabis Cannabinoids)
- "We also designed to provide a holistic evaluation by considering both clinical outcomes and the underlying biological mechanisms, including the interaction with the human microbiome. Through this trial, we aim to contribute valuable insights into personalized psoriasis management strategies."
Clinical • Journal • Dermatology • Dermatopathology • Immunology • Psoriasis
1 to 2
Of
2
Go to page
1